---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-169252"
form_type: "8-K"
ticker: "SPRO"
cik: "0001701108"
company_name: "Spero Therapeutics, Inc."
filed_at: "2022-06-07T23:59:59+00:00"
generated_at: "2026-06-25T03:59:38.362128+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Spero pays $54.5M to terminate HCR revenue interest agreement, regains Tebi asset rights

## Summary
- Cash payment of $54.5M (exact $54,484,895) on June 7, 2022 to terminate HCR financing agreement and release all liens.
- All rights to tebipenem (Tebi) assets revert to Spero; company previously ceased Tebi commercialization on May 3, 2022.
- Contingent additional payment of up to $10M+ if a change of control occurs by Dec 31, 2022, based on equity value.

## SEC filing metadata
- accession: 0001193125-22-169252
- form_type: 8-K
- ticker: SPRO
- cik: 0001701108
- company_name: Spero Therapeutics, Inc.
- filed_at: 2022-06-07T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701108/000119312522169252/0001193125-22-169252-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701108/000119312522169252/d271182d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-169252
- JSON: https://secwatch.observer/filing/0001193125-22-169252.json
- Plain text: https://secwatch.observer/filing/0001193125-22-169252.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.